FDA Expands Indication for Urticaria Drug to Treat Symptomatic Dermographism
(MedPage Today) -- The FDA expanded the indication of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib (Rhapsido) to treat symptomatic dermographism, the most common form of chronic inducible urticaria, Novartis announced Thursday. The...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.